Recent discoveries indicate that transcriptional elongation is an important regulatory step in gene expression, and that deregulation of elongation can lead to the development of certain malignancies.
It is well established that deregulation of transcription can cause cancer, and the protein products of many oncogenes, proto-oncogenes and tumor suppressor genes are transcription factors. It has been assumed that the deregulation would occur at the level of initiation, the first step in transcription and the one that has commanded most attention. However, two recent findings call that assumption into question by showing that the deregulation can also occur at the level of transcriptional elongation.
The von Hippel-Lindau syndrome is a hereditary disorder that predisposes affected individuals to multiple forms of cancer. The disease is caused by the lack of expression, or mutation, of the VHL gene, the product of which is therefore a tumor suppressor [1] . To gain insight into the function of the VHL gene product, several groups have analyzed the proteins with which pVHL interacts [2, 3] . Two polypeptides were identified that associate with a region of pVHL that is frequently mutated in tumors of patients with von Hippel-Lindau syndrome. Unexpectedly, these polypeptides correspond to the B and C subunits of a well characterized transcriptional elongation factor, Elongin (SIII).
Elongin (SIII) is comprised of three subunits [4] . Whereas Elongin A can, by itself, stimulate elongation, its activity is enhanced by the other two subunits, Elongin B and C. These observations, and other in vitro results [2, 3] , suggest that pVHL normally binds to, and sequesters, Elongin B and C, thereby downregulating Elongin (SIII)-mediated transcriptional elongation. In afflicted individuals, the mutation (or absence) of pVHL prevents binding to Elongin B and C and therefore transcriptional elongation is inappropriately upregulated (Fig. 1) .
A further indication that pVHL plays a central role in growth control is that its cellular localization changes in response to cell density: pVHL is nuclear in sparsely cultured cells and cytoplasmic in densely cultured cells [5] . However, this localization pattern is opposite to that expected if pVHL is acting to suppress cellular proliferation. This curiosity remains to be explained.
The second connection between cancer and transcriptional elongation comes from studies of the ELL (also called MEN ) gene, first identified in a chromosomal translocation, t(11;19)(q23;p13.1), implicated in certain acute myeloid leukemias [6] . Whereas the sequence of the ELL protein did not reveal its function, a recent study [7] found that it is a biochemically defined elongation factor. Two proteins have thus recently been implicated in cancer, of which one, pVHL, regulates transcriptional elongation, whereas the other, ELL, is itself a transcriptional elongation factor.
These new findings strongly reinforce the notion that gene expression can be controlled at the level of transcriptional elongation and raise the question: how does deregulation Regulation of transcription by the von HippelLindau tumor suppressor gene product pVHL. The transcription elongation factor Elongin (SIII) is a complex of subunits A, B, and C: subunit A contains intrinsic elongation activity, which is stimulated by interaction with subunits B and C. In normal cells, wild type pVHL regulates Elongin (SIII) activity by sequestering Elongin B and C, preventing their association with Elongin A. In VHL cells, Elongin B and C associate with Elongin A in an unchecked manner, resulting in unregulated elongation. of elongation result in cancer? The answer, presumably, is by affecting the expression of a particular target gene(s) whose product is involved in growth control. In fact, some genes involved in growth control, such as c-myc and c-fos, have been long known to be controlled, at least in part, at a post-initiation step [8] . However, this hardly narrows the field; many genes are presumably regulated at the transcriptional elongation level. For example, immunofluorescence studies of Drosophila polytene chromosome have detected the association of RNA polymerases with many non-transcribed genes, suggesting that regulation occurs at a post-initiation step [9] .
A recent study suggests that pausing of RNA polymerase II in the promoter-proximal region occurs under a variety of conditions, and may be a general rate-limiting step in transcription [10] . Furthermore, a generic basal promoter, containing a TATA box or initiator element, is sufficient to direct formation of a nonprocessive elongation complex. In fact, in vitro transcription studies suggest that basal elongation is very inefficient and is subject to 'road blocks' such as certain DNA sequences and nucleosomes [8] .
Thus, transcriptional pausing may be the 'default' state, which must be overcome by regulator proteins, presumably promoter-specific transcriptional activators.
Most studies on activators have focused exclusively on their ability to stimulate transcriptional initiation. Recent studies, however, have shown that activators can also regulate transcriptional elongation. Importantly, there are significant differences amongst activators in their ability to stimulate elongation [10, 11] . The processivity of an elongation complex may therefore depend upon the composition of activators at the promoter. This may help explain why a general alteration in the elongation machinery can have apparent gene-specific effects.
The molecular mechanisms by which promoter-bound activators regulate transcriptional elongation is poorly understood. Some studies have shown that paused and active elongation complexes differ from one another in the phosphorylation status of the carboxy-terminal domain (CTD) of RNA polymerase II [9, 12] . Thus, activators may stimulate transcriptional elongation by promoting phosphorylation of the RNA polymerase II CTD. Alternatively, activators may recruit an 'elongation stimulatory factor' to the elongation complex; this is believed to be the mechanism by which the human immunodeficiency virus type 1 (HIV-1) transactivator Tat protein functions [13] .
Transcriptional elongation is thus emerging as an important regulatory step in gene expression and cell growth control. While regulation of elongation is currently poorly understood, the recent findings provide an additional incentive and new reagents to attack this problem.
